Inflammation induced by human papillomavirus in cervical cancer and its implication in prevention

European Journal of Cancer Prevention

Volumn 23, Issue 5, 2014, Pages 432-448

  Parida, Sheetal ^a   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

Author keywords

cancer prevention; cervical cancer; COX 2; cyclooxygenases; inflammation; prostaglandins; prostanoid receptors

Indexed keywords

ALPHA TOCOPHEROL; CELECOXIB; CHEMOKINE; CISPLATIN; CYCLOOXYGENASE 2; CYTOKINE; FOLIC ACID; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; ONCOPROTEIN; PROSTAGLANDIN E2; PROSTANOID; PROTEIN E5; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS PROTEIN; WART VIRUS VACCINE;

CANCER INCIDENCE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VIRUS ONCOGENE; WART VIRUS; COMPLICATION; FEMALE; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PATHOLOGY; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

FEMALE; HUMANS; INFLAMMATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 84905379743     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000023     Document Type: Review

References (126)

1. Adefuye A, Sales K (2012). Regulation of inflammatory pathways in cancer and infectious disease of the cervix. Scientifica 2012:1-8.
2. Aggarwal BB (2003). Signalling pathways of the TNF superfamily: a doubleedged sword. Nat Rev Immunol 3:745-756.
3. Aggarwal BB (2004). Nuclear factor-kappaB: the enemy within Cancer. Cell 6:203-208.
4. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006). Inflammation and cancer: How hot is the link? Biochem Pharamacol 72:1605-1621.
5. Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikäheimo I, et al. (2001). Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285:47-51.
6. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, Bray F, et al. (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675-2686.
7. Ashby B (1998). Co-expression of prostaglandin receptors with opposite effects: a model for homeostatic control of autocrine and paracrine signaling. Biochem Pharmacol 55:239-246.
8. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM (1987). Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962-967.
9. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357:539-545.
10. Balkwill F, Coussens LM (2004). Cancer: an inflammatory link. Nature 431: 405-406.
11. + CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 83:6779-6789.
12. Biswas SK, Mantovani A (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896.
13. Boccardo E, Lepique AP, Villa LL (2010). The role of inflammation in HPV carcinogenesis. Carcinogenesis 31:1905-1912.
14. Bogdan C (2001a). Nitric oxide and the immune response. Nat Immunol 2: 907-916.
15. Bogdan C (2001b). Nitric oxide and the regulation of gene expression. Trends Cell Biol 11:66-75.
16. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001). Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690.
17. Brune B, Knethen AV, Sandau KB (1999). Nitricoxide (NO): an effector of apoptosis. Cell Death Differ 6:969-975.
18. Burgel HT, Stiehl DP, Wagner AE, Metzen E, Jelkmann W (2005). Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 25:297-310.
19. Canadas MP, Videla S, Darwich L, Tarratse A, Pinol M, Garcia-Cuyasf F, et al. (2010). Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected women. J Clin Virol 48:198-201.
20. Cao Y, Prescott SM (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279-286.
21. Carter JR, Ding Z, Rose BR (2011). HPV infection and cervical disease: a review. Aust N Z J Obstet Gynaecol 51:103-108.
22. Castle PE, Hillier SL, Rabe LK, Hildesheim A, Herrero R, Bratti MC, et al. (2001). An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10:1021-1027.
23. Castle PE, Giuliano AR (2003). Genital tract infections, cervical inflammation, and antioxidant nutrients - assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 31:29-32.
24. Chandrasekharan NV, Simmons DL (2004). The cyclooxygenases. Genome Biol 5:241.
25. Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL (2001). The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 8:206-213.
26. Chang YW, Jakobi R, McGinty A, Foschi M, Dunn MJ, Sorokin A (2000). Cyclooxygenase 2 promotes cell survival by stimulation of dye in light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 20:8571-8579.
27. Chen D, Tang Q (2010). An experimental study on cervix cancer with combination of HSV-TK/GCV suicide gene therapy system and 60Co radiotherapy. BMC cancer 10:609-615.
28. Choy H, Milas L (2003). Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95:1440-1452.
29. Chung SH, Franceschi S, Lambert PF (2010). Estrogen and ERa: culprits in cervical cancer? Trends Endocrinol Metab 21:504-511.
30. Conrad M, Bubb VJ, Schlegel R (1993). The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol 67:6170-6178.
31. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420:860-867.
32. Da Silva Cardeal LB, Brohem CA, Correa TC, Winnischofer SM, Nakano F, Boccardo E (2006). Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol 84:713-719.
33. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254-266.
34. Denny L (2008). Prevention of cervical cancer. Reprod Health Matters 16:18-31.
35. Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, et al. (2002a). Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 87: 1145-1152.
36. Ferrandina G, Lauriola L, Zannoni GF, Faggoti A, Fanfani F, Legge F, et al. (2002b). Increased cyclooxygenase-2(COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205-1211.
37. Ferrandina G, Ranelletti FO, Lauriola L, Fanfani F, Legge F, Mottolese M, et al. (2002c). Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol 85:305-310.
38. Finnen RL, Erickson KD, Chen XS, Gracea RL (2003). Interaction between papillomavirus L1 and L2 capsid proteins. J Virol 77:4818-4826.
39. Franco EL, Harper DM (2005). Vaccination against humanpapillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23:2388-2394.
40. Frazer IH (2004). Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4:46-54.
41. Gaffney DK, Holden J, Davis M, Zenpolich K, Murphy K, Dodson M (2001). Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213-1217.
42. Gonzalez AD, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E (2005). Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4:1-24.
43. Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
44. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell 118:285-296.
45. Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006). Cyclooxygenase-2 (COX-2) - independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736-747.
46. Grossmann J (2002). Molecular mechanisms of detachment induced apoptosis - anoikis. Apoptosis 7:247-260.
47. Hausen H (2003). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:691-698.
48. Hausen H (2009). Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260-265.
49. Heitbrock LZ (2007). The CD14 + CD16 + blood monocytes: their role in infection and inflammation. J Leukoc Biol 81:584-592.
50. Henstermann A, Linares LK, Ciechanover A (2001). Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98:1218-1223.
51. Hinz B, Brune K (2002). Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 300:367-375.
52. Hinz B, Cheremina O, Brune K (2008). Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22:383-390.
53. Honjo S, Osaki M, Ardyanto TD, Hiramatsu T, Maeta N, Ito H (2005). COX-2 inhibitor, NS398, enhances fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 24:141-147.
54. Houghton AM (2010). The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9:1732-1737.
55. Howley PM, Scheffner M, Munger K (1991). Oncoproteins encoded by the cancer-associated papillomavirus target the products of retinoblastoma and p53 tumor suppressor genes. Cold Spring Harb Symp Quant Biol 56: 149-155.
56. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000). The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403.
57. Hu X, Schwarz JK, James S, Lewis JS Jr, Huettner PC, Rader JS (2010). A microRNA expression signature for cervical cancer prognosis. Cancer Res 70:1441-1448.
58. Irwin MS, Miller FD (2004). p73: regulator in cancer and neural development. Cell Death Differ 11:S17-S22.
59. Jacobs N, Giannini SL, Doyen J, Baptista A, Moutschen M, Boniver J, et al. (1998). Inverse modulation of IL-10 and IL-12 in blood of women with preneoplastic lesions of uterine cervix. Clin Exp Immunol 111:219-224.
60. Jayadev S, Linardic CM, Hannun YA (1994). Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor a. J Biol Chem 269:5757-5763.
61. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. (1999). Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
62. Kawasaki H, Taira K (2005). Transcriptional gene silencing by short interfering RNAs. Curr Opin Mol Ther 7:125-131.
63. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, et al. (2004). Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10:1366-1374.
64. Kim MK, Kim HS, Kim SH, Oh JM, Han JY, Lim JM, et al. (2010). Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol 80:1930-1935.
65. Kim N, Kim CH, Ahn DW, Lee KS, Cho SJ, Park JH, et al. (2009). Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. J Gastroenterol Hepatol 24:480-487.
66. Kim YB, Kim GE, Cho NH, Pyo HY, Shim SJ, Chang SK, et al. (2002). Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95:531-539.
67. Kis B, Snipes JA, Isse T, Nagy K, Busija DW (2003). Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 23:1287-1292.
68. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. (2011). IRF5 promotes inflammatory macrophage polarization and T H1- TH17 responses. Nat Immunol 12:231-238.
69. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL (2001). Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7:429-434.
70. La Vecchia C, Bosetti C (2003). Oral contraceptives and cervical cancer: public health implications. Eur J Cancer Prev 12:1-2.
71. Lau LM, Wolter JK, Lau JT, Cheng LS, Simth KM, Hansford LM, et al. (2009). Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28:2024-2033.
72. Lee KA, Kang JW, Shim JH, Chang WK, Sung GP, Hee GL, et al. (2005). Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics. Gynecol Oncol 99:142-152.
73. Levine AM (1993). AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst 85:1382-1397.
74. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F (2009). Uterine cervical carcinoma: role of matrix metalloproteinases. Int J Oncol 34:897-904.
75. Lin WW, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 117:1175-1183.
76. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RBS (2009). Combination of proteasome and HDAC inhibitors for therapy of uterine cervical cancer. Clin Cancer Res 15:570-577.
77. Liou JY, Ghelani D, Yeh S, Wu KK (2007). Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3∈. Cancer Res 67:3185-3191.
78. Liu DW, Yang YC, Lin HF, Fang M, Cheng YW, Chu CC, et al. (2007). Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J Virol 81:2869-2879.
79. Liu H, Xiao J, Yang Y, Liu Y, Ma R, Li Y, et al. (2011). COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res 82:131-140.
80. Mahdavi A, Monk BJ (2005). Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 10:528-538.
81. Martin S, Phillips DC, Szucs KS, Elghazi L, Desmots F, Houghton JA (2005). Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65:11447-11458.
82. Menter DG, DuBois RN (2012). Prostaglandins in cancer cell adhesion, migration and invasion. Int J Cell Biol 2012:1-21.
83. Munger K, Howley PM (2002). Human papillomavirus immortalization and transformation functions. Virus Res 89:213-228.
84. Narumiya S, Fitz Gerald GA (2001). Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108:25-30.
85. Negus RPM, Stamp GWH, Hadley J, Balkwill FR (1997). Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150:1723-1734.
86. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, Rozendaal L, Remmink AJ, Risse EKJ, et al. (1999). Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354:20-25.
87. Nuovo GJ, MacConnell PB, Simsir A, Valea F, French D (1995). Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55:267-275.
88. Oelze I, Kartenbeck J, Crusius K, Alonso A (1995). Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line. J Virol 69:4489-4494.
89. Oh JM, Kim SH, Lee Y, Seo M, Kim SY, Song YS, et al. (2009). Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogeneis 30:141-149.
90. Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS (2010). Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 3:402-410.
91. Pal I, Mandal M (2012). PI3K and Akt as molecular targets for cancer therapy: Current clinical outcomes. Acta pharmacol Sin 33:1441-1458.
92. Pettus BJ, Chalfant CE, Hannun YA (2002). Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 1585:114-125.
93. Ramsay RG, Ciznadija D, Vanevski M, Mantamadiotis T (2003). Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 16:59-67.
94. Rock CL, Michael CW, Reynolds RK, Ruffin MT (2000). Prevention of cervix cancer. Crit Rev Oncol Hematol 33:169-185.
95. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS (2000). High cyclooxygenase-2 expression in stage 1B cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76:320-325.
96. Sahebalia S, Van den Eyndenc G, Murta EF, Michelin MA, Cusumano P, Petignat P, et al. (2010). Stromal issues in cervical cancer: a review of the role and function of basement membrane, stroma, immune response and angiogenesis in cervical cancer development. Eur J Cancer Prev 19:204-215.
97. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyer MD, et al. (2001). Cyclooxygenase-2 expression and prostaglandin E2 synthesis are upregulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243-2249.
98. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN (2002). Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62:424-432.
99. Sales KJ, Katz AA (2012). Inflammatory pathways in cervical cancer - the University of Cape Town's contribution. S Afr Med J 102:493-496.
100. Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, et al. (2005). Gene expression profiles of primary HPV 16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 331:269-291.
101. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007). Human papillomavirus and cervical cancer. Lancet 370:890-900.
102. Shimohama S (2000). Apoptosis in Alzheimer's disease - an update. Apoptosis 5:9-16.
103. Shishodia S, Aggarwal BB (2004). Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol 68:1071-1080.
104. Singh GK, Azuine RE, Siahpush M (2012). Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH AIDS 1:17-30.
105. Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J, et al. (2002). Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 94:1604-1613.
106. 14C]-arachidonic acid by human colonic mucosa. Gut 24:1176-1182.
107. Smith WL, DeWitt DL, Garavito RM (2000). Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
108. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010). The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010:1-21.
109. Stanley MA, Pett MR, Coleman N (2007). HPV: from infection to cancer. Biochem Soc Trans 35:1456-1460.
110. Straight SW, Herman B, McCance DJ (1995). The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 69:3185-3192.
111. Stubenrauch F, Laimins LA (1999). Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol 9:379-386.
112. Stubenrauch F, Zoble T, Iftner T (2001). The E8 domain confers a novel longdistance transcriptional repression activity on the E8 E2C protein of high-risk human papillomavirus type 31. J Virol 75:4139-4149.
113. Subbaramaiah K, Dannenberg AJ (2007). Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res 67:3976-3985.
114. Tan TT, Cousse LM (2007). Humoral immunity, inflammation and cancers. Curr Opin Immunol 19:209-216.
115. Taylor WR, Stark GR (2001). Regulation of the G2/M transition by p53. Oncogene 20:1803-1815.
116. Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S, Desaintes O (2004). A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer Res 64:895-903.
117. Tindle RW (2002). Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2:59-64.
118. Tomakidi P, Cheng H, Kohl A, Komposch G, Alonso A (2003). Connexin 43 expression is downregulated in raft cultures of human keratinocytes expressing the human papillomavirus type 16 E5 protein. Cell Tissue Res 301:323-327.
119. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716.
120. Valle GF, Banks L (1995). The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 76:1239-1245.
121. Ward P, Coleman DV, Malcolm DB (1989). Regulatory mechanisms of the papillomavirus. Trends Genet 5:97-99.
122. Wei L, Gravitt PE, Song H, Maldonado AM, Ozbun MA (2009). Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res 69: 4878-4884.
123. Woodgett JR (1994). Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin Cancer Biol 5:269-275.
124. Woodworth CD, McMullin E, Iglesias M, Plowman GD (1995). Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinomaderived cervical epithelial cells. Proc Natl Acad Sci USA 92:2840-2844.
125. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26:827-834.
126. Yu KJ, Rader JS, Borecki I, Zhang Z, Hildesheim A (2009). CD83 Polymorphisms and Cervical Cancer Risk. Gynecol Oncol 114:319-322.